← Back to All Filings

Amgen SVP Sells ~$300k in AMGN Stock in Routine Transaction

Low SignificanceNovember 13, 2025 at 7:32:15 PM EST

AMGEN INC

$AMGN4CIK: 0000318154

Subscribe to track AMGN

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Amgen SVP Sells ~$300k in AMGN Stock

Company: AMGEN INC (AMGN) Form: 4 | Filed: 2025-11-13 Significance: Low

Insider: Khosla Rachna Title: SVP, Business Development | Relationship: Officer

Transaction: • Type: Sell • Shares: 890 • Price: $336.24 • Value: $299,256 • Owned After: 7,082

Key Insight: An SVP sold a small portion of her holdings (~11%) in a transaction valued at approximately $300k. This is a routine, non-material sale for a mega-cap company like Amgen.

Market Context: The transaction value represents less than 0.0002% of Amgen's $174.28 billion market capitalization, indicating no significant market impact.

Comprehensive Analysis

SEC Filing Analysis: AMGEN INC (AMGN)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: A senior executive at Amgen conducted a small, routine sale of company stock, likely for personal financial management.
  • Market Impact: The transaction is negligible in the context of Amgen's massive market capitalization and is not expected to influence the stock's performance.

Company Information

FieldValue
CompanyAMGEN INC
Ticker SymbolAMGN
CIK0000318154
IndustryBiological Products

Insider Information

FieldValue
NameKhosla Rachna
CIK0001881332
Title/PositionSVP, Business Development
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-12
Transaction CodeS (Open market or private sale)
Security TypeCommon Stock
Shares Involved890
Price Per Share$336.2422
Total Value$299,255.56
Shares Owned After7,082
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$299,255.56
% of Market Cap0.00017%
Shares Transacted890
% of Shares Outstanding0.000165%
Post-Transaction Ownership7,082 shares (0.0013% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: As a mega-cap company with a market capitalization of $174.28 billion, this transaction of approximately $300k is financially insignificant to the company and the market.
  • Ownership Concentration: The insider's post-transaction holding of 7,082 shares represents a very small fraction (0.0013%) of the total shares outstanding, indicating low ownership concentration from this individual.
  • Transaction Significance: The sale represents a minor portfolio adjustment for the insider and is immaterial from a corporate perspective, falling far below any thresholds for significance.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction's value and share count are too small relative to Amgen's market size and daily trading volume to have any discernible effect on the stock price.

Volume & Sentiment

  • Expected Volume Impact: None. The transaction is a negligible fraction of typical daily trading volume.
  • Sentiment Indicator: Neutral. The market will likely view this as a routine, non-eventful insider transaction.

Additional Context

Transaction Notes

  • Special Circumstances: The reported price is a weighted average. The shares were sold in multiple transactions at prices ranging from $336.2219 to $336.30.
Topics:#SECFiling#InsiderTrading#AMGN#Amgen#Form4#InsiderSell#StockMarket#Investing#Biotech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.